Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will ...

The press release will be available in the Investors section of Cellectis’ website: Cellectis will not host a conference call to discuss these results. Our investors relations team remains available ...

Following the removal of the Caveat Emptor designation, Protext Mobility Inc. (OTC: TXTM) has entered a new phase of growth — one built on transparency, accountability, and leadership alignment.

About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases.

Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company, today announces the acquisition of 100 Bitcoin, at an average price of $109,594 per Bitcoin.

Company to Host Conference Call on November 10, 2025, at 4:30 p.m. ET ...

Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced the initiation of a new research and development ...

COPENHAGEN, Denmark, October 31, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business ...

Published in the Oct. 30, 2025 edition of Frontiers in Pharmacology, the new post-hoc analysis showed that patients who took the GeneSight test were at any given time during the 24-week study period ...

COPENHAGEN, Denmark, October 31, 2025 – Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley ...

Live webcasts of the fireside chats will be available through the investor relations section of the Company's website at ir.discmedicine.com and an archived replay will be available after each event.

IntoCell Inc. (KOSDAQ: 287840), a biotechnology company developing next-generation payload and linker technologies for antibody–drug conjugates (ADCs), and Xcellon Biologics, a U.S.-based contract ...